🔗 Permalink

Assignee profile:

NBE Therapeutics AG

City:

Basel

Country:

Switzerland

Published Applications:

Last publication date:

2022-12-01

Patent Grants:

Last grant date:

2024-05-21

Top Inventors for applications by NBE Therapeutics AG

These are the the leading inventors for applications assigned to NBE Therapeutics AG:

Ulf Grawunder 9 Hersberg, Switzerland
Roger Renzo BEERLI 8 Basel, Switzerland
Ulf Grawunder 8 Basel, Switzerland
Lorenz Waldmeier 6 Basel, Switzerland

Roger BEERLI 5 Adlikon bei Regensdorf, Switzerland
Rémy Gébleux 2 Olten, Switzerland
Roger Beerli 2 Adlikon, Switzerland
Roger BEERLI 2 Aldikon bei Regensdorf, Switzerland

Christoph Rader 2 Jupiter, FL United States
Remy GEBLEUX 2 Basel, Switzerland
Haiyong Peng 2 Jupiter, FL United States
Ina Hellmann 2 Huningue, France

Georg LIPPS 1 Riehen, Switzerland
Chasper PUORGER 1 Basel, Switzerland
Ina HELLMANN 1 Basel, Switzerland
Salvatore DI GIROLAMO 1 Basel, Switzerland

Recent patent applications by NBE Therapeutics AG

NBE Therapeutics AG based in Basel, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2022-12-01 ✅ Patent 11,986,535 granted on 2024-05-21

US20220378927A1

Human necessities

Method of producing an immunoligand/payload conjugate

#2 | 2022-11-24 ✅ Patent 12,275,789 granted on 2025-04-15

US20220372143A1

Chemistry; metallurgy

Human antibodies binding to ROR2

#3 | 2021-12-09 ✅ Patent 12,533,420 granted on 2026-01-27

US20210379196A1

Human necessities

SORTASE F AND ITS USE IN METHODS FOR CONJUGATION

#4 | 2021-10-21 ✅ Patent 11,833,120 granted on 2023-12-05

US20210322561A1

Human necessities

Binding protein drug conjugates comprising anthracycline derivatives

#5 | 2021-01-28 ✅ Patent 12,121,527 granted on 2024-10-22

US20210023103A1

Human necessities

Anthracycline-based antibody drug conjugates having high in vivo tolerability

#6 | 2021-01-21 ✅ Patent 11,364,301 granted on 2022-06-21

US20210015936A1

Human necessities

Method of producing an immunoligand/payload conjugate

#7 | 2020-11-12 ✅ Patent 11,447,546 granted on 2022-09-20

US20200354449A1

Chemistry; metallurgy

Human antibodies binding to ROR2

#8 | 2020-09-24 ✅ Patent 11,242,388 granted on 2022-02-08

US20200299381A1

Chemistry; metallurgy

ROR1 antibody compositions and related methods

#9 | 2020-03-26 ✅ Patent 10,960,083 granted on 2021-03-30

US20200093933A1

Human necessities

Binding protein drug conjugates comprising anthracycline derivatives

#10 | 2019-12-19 ✅ Patent 10,758,556 granted on 2020-09-01

US20190381079A1

Human necessities

Anthracycline-based antibody drug conjugates having high in vivo tolerability

#11 | 2019-08-29 ✅ Patent 10,864,277 granted on 2020-12-15

US20190262461A1

Human necessities

Method of producing an immunoligand/payload conjugate

#12 | 2019-05-23 ✅ Patent 11,845,793 granted on 2023-12-19

US20190153092A1

Chemistry; metallurgy

Anti-ROR1 antibodies

#13 | 2019-05-02 ✅ Patent 10,517,959 granted on 2019-12-31

US20190125892A1

Human necessities

Binding protein drug conjugates comprising anthracycline derivatives

#14 | 2019-04-18

US20190112385A1

Chemistry; metallurgy

ANTI-MESOTHELIN ANTIBODIES

#15 | 2018-11-29 ✅ Patent 10,618,959 granted on 2020-04-14

US20180340026A1

Chemistry; metallurgy

ROR1 antibody compositions and related methods

#16 | 2017-12-21 ✅ Patent 10,188,745 granted on 2019-01-29

US20170360953A1

Human necessities

Binding protein drug conjugates comprising anthracycline derivatives

#17 | 2016-05-19 ✅ Patent 9,872,923 granted on 2018-01-23

US20160136298A1

Human necessities

Method of producing an immunoligand/payload conjugate

Also check out NBE-Therapeutics AG's (Basel, Switzerland) applicant profile with 17 patent applications submitted.

AssigneeID:

108323 ⎘